Intellia (NTLA) Up on Deal With ONK for Cancer Therapies Posted byZacks Equity Research February 16, 2022 Leave a comment on Intellia (NTLA) Up on Deal With ONK for Cancer Therapies Intellia (NTLA) partners with ONK Therapeutics. The collaboration utilises their respective proprietary platforms to develop allogeneic CRISPR-based NK cell therapies for the treatment of cancer.